Rheumatoid arthritis symptoms; This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID ARTHRITIS (Rheumatoid arthritis symptoms) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On an unknown date, the patient experienced RHEUMATOID ARTHRITIS (Rheumatoid arthritis symptoms) (seriousness criterion medically significant). At the time of the report, RHEUMATOID ARTHRITIS (Rheumatoid arthritis symptoms) was resolving.            No concomitant medications were reported. On 21-Nov-2021, the patient received a booster dose of Moderna vaccine. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The reporter causality for the event of Rheumatoid arthritis symptoms with Humira (Adalimumab) was reported as reasonable possibility.  No treatment medications were reported. Company Comment: This spontaneous case concerns an   adult  female  patient with no age reported , with relevant concurrent medical condition of rheumatoid arthritis  with reported Co-suspect non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis, This patient  experienced Serious ( Medically significant ) , unexpected , AESI of rheumatoid arthritis which occurred on an unknown date with vaccination with the three doses of mRNA-1273 vaccine.The date of onset of the event was not reported hence  onset latency of event can't be assessed.  No other information surrounding the event was provided. Outcome of the event was reported as resolving.  The concurrent medical history of Rheumatoid arthritis of this patient and the Co-suspect non-company product  ADALIMUMAB (HUMIRA) are considered as confounders for the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns an   adult  female  patient with no age reported , with relevant concurrent medical condition of rheumatoid arthritis  with reported Co-suspect non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis, This patient  experienced Serious ( Medically significant ) , unexpected , AESI of rheumatoid arthritis which occurred on an unknown date with vaccination with the three doses of mRNA-1273 vaccine.The date of onset of the event was not reported hence  onset latency of event can't be assessed.  No other information surrounding the event was provided. Outcome of the event was reported as resolving.  The concurrent medical history of Rheumatoid arthritis of this patient and the Co-suspect non-company product  ADALIMUMAB (HUMIRA) are considered as confounders for the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.